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Costs of Early Adjuvant Radiation 
Therapy After Radical Prostatectomy: 
A Decision Analysis
Purpose/Objective(s)
Prospective, randomized trials support adjuvant radiation therapy 
(RT) for adverse pathologic features after radical prostatectomy (RP). 
However, adjuvant RT is not universally delivered in this setting. 
Criticisms of adjuvant RT include toxicity, financial costs, potential 
overtreatment, and effectiveness of salvage RT. The objective of this 
study was to construct a decision analytic model to estimate real world 
cost of RT vs. no RT within the context of the effectiveness of early 
adjuvant RT for prostate patients based on published clinical results 
of the Southwest Oncology Group prospective trial of adjuvant RT 
(SWOG 8794).
Materials/Methods
A decision analysis was constructed in TreeAge Pro 2009 to compare 
adjuvant RT versus no RT for patients with adverse pathologic 
features after RP over 10 years. Treatment success was defined as the 
absence of PSA failure (PSA < 0.2 ng/mL). Probabilities of treatment 
success (instance of biochemical control), salvage RT, ADT, and 
adverse events (AEs) were taken from published results of SWOG 
8794. Cost inputs included adjuvant RT, ADT, salvage RT, and 
management of AEs due to ADT and RT. Costs were based on 2010 
Medicare reimbursement rates, assuming that 4-field, conformal RT 
was delivered to 60-64 Gy. A series of one-way sensitivity analyses 
were conducted to evaluate the relative importance of each cost and 
probability assumption on the model. Mean incremental costs for RT 
versus no RT were calculated from the model results and applied to 
the incremental successes per 100 patients from SWOG 8794.
Results
Per SWOG 8794, early adjuvant RT versus no RT results in a higher 
PSA success rate with 58 vs. 28 successes or 30 incremental PSA 
successes with RT per 100 treated men. Preliminary model results 
show that the mean incremental cost per patient was $7,506, or 
$750,600 per 100 men, treated with versus without adjuvant RT. The 
incremental cost per success for early adjuvant RT was $2,502 per 
patient, per year, over the 10 year time horizon. Sensitivity analyses 
revealed the model to be most sensitive to the likelihood of treatment 
failure and ADT cost. Findings were moderately sensitive to RT cost.
Conclusion
This decision analysis of adjuvant RT, versus no RT, after RP for 
patients with adverse pathologic features, estimates an incremental 
cost per success of $25,020 over 10 years, under the assumption 
that the doubling of treatment success seen in SWOG is realized in 
clinical practice. This model provides a baseline for further analysis 
of the incremental costs when using IMRT in the post-RP setting, and 
can be used to test potential cost reductions that can be achieved with 
hypofractionation. Furthermore, this model provides a foundation 
for subsequent cost comparisons for adjuvant RT versus close 
surveillance and selective salvage RT after RP.
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